Navigation Links
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

MINNEAPOLIS, Aug. 24 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II").

The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral vasculature. The Amplatzer Vascular Plug II is a self- expandable nitinol mesh occlusion device and is designed to be introduced in a minimally invasive fashion through a catheter. The delivery cable that comes pre-attached uses the unique AMPLATZER user interface to enable the physician to more precisely position the device in the targeted blood vessel. Once positioned, the cable is unscrewed and the device is released. The vascular plug II is designed with multiple lobes to facilitate rapid clotting.

"I have used the new Amplatzer Vascular Plug and I found it to be very easy to use and very effective in causing a quick and complete occlusion, said Dr. James F. Benenati, Medical Director of the Peripheral Vascular Lab at the Baptist Cardiac & Vascular Institute in Miami, Florida. "Deployment is easy, radio-opacity is excellent and occlusion is complete and rapid."

The vascular plug two comes in sizes ranging from 3 mm to 22 mm enabling treatment of a wider range of vessel sizes. Unlike competing devices, a single vascular plug II is generally required to occlude the targeted vessel making it a cost and time effective alternative.

"The new vascular plug is an important addition to our family of occlusion devices", said Franck Gougeon, President and CEO of AGA. "The vascular plug is among the fastest growing AGA products and we believe this new model can only help to further accelerate its growth. With more products under development that are specifically targeted for use by interventional specialists that treat peripheral vascular disease, the vascular plug is establishing a strong and exciting foundation for future diversification by AGA Medical."

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. Over 700 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 250,000 devices shipped to date. For more information visit


Devin Nagy

Brunswick Group LLC


SOURCE AGA Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use ... promoted Melanie Aregger to serve as Chief Operating Officer. , Having joined ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 companies ... dominated by a few companies, according to Kalorama Information. These ... 51% of the market share of the 6.1 billion-dollar ... The World Market for Molecular Diagnostic s .    ... market is still controlled by one company and only ...
Breaking Biology News(10 mins):